hims weight loss semaglutide GLP-1 Guide 2026: Injectable and Oral Treatment Options for Men (Semaglutide and Tirzepatide) Hims & Hers Health stock

ATTAIN-1 Trial Highlights: - Mean weight loss of ~12.4% over 72 weeks for patients on the highest dose - Participants lost an average of 25 pounds (11.1%) regardless of trial completion - Safety profile consistent with GLP-1 class

For more detailed information about our services please download our brochures

Semaglutide does not directly cause primary headaches

Recent Findings Newer generation GLP-1 based therapies have become more effective for the treatment of overweight and obesity, with data supporting tirzepatide as the most effective, followed by semaglutide and then liraglutide

GLP-1 therapies can boost a members weight loss, but there have to be lifestyle changes to sustain it. - Arpit Patel, PharmD, SVP of Trade Relations & Supply Chain